2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2303

Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011
Abstract Number: 1505

Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013
Abstract Number: 2331

Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis
Abstract Number: 1365

Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Abstract Number: 1510

Trends in the Occurrence of Malignancy in Japanese Patients with Rheumatoid Arthritis Based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort during a 14-Year Observation Period
Abstract Number: 568

Triggering Receptor Expressed on Myeloid Cells (TREM) As a Novel Indicator of Disease Progression in ‘at-Risk’ Individuals
Abstract Number: 2581

Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis
Abstract Number: 1675

Triptolide Inhibits Th17 Differentation By JAK2/STAT3 Signal Pathway in Inflammation of Ankylosing Spondylitis
Abstract Number: 2006

Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Abstract Number: 964

Tubulointerstitial Damage Is an Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild to Moderate Renal Impairment
Abstract Number: 2557

Tumor Necrosis Factor (TNF) Sensitizes Rheumatoid Synovial Fibroblasts to TRPA1-Mediated Calcium Flux, Anti-Proliferation and Cell Death
Abstract Number: 2982

Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 1129

Tumor Necrosis Factor Receptor 2 Is Crucial for Regulatory T Cells Activity with Consequences in a Model of Chronic Inflammation and in Anti-TNF Treated Rheumatoid Arthritis
Abstract Number: 382

Tumor Necrosis Factor-α -308 a/G Gene Polymorphism in Children with Juvenile Idiopathic Arthritis: Relation to Disease Activity, Damage and Disability
Abstract Number: 19

Tumour Necrosis Factor Inhibition Is Associated with Weight Gain in Patients with Inflammatory Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].